Cellect Biotechnology Ltd. Form 6-K Summary
Business Context and Reporting Period
This Form 6-K was filed by Cellect Biotechnology Ltd. (a foreign private issuer) on October 25, 2017. The filing incorporates by reference a press release dated October 25, 2017, announcing a major breakthrough in the company's ApoGraft technology.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This document serves as a notification of a clinical trial update rather than a financial report.
Material Changes and Clinical Update
The primary material event reported is the positive results from a clinical trial involving 20 patients conducted with Tel-Aviv Ichilov Medical Center. The company describes these results as a "major breakthrough" for its ApoGraft technology.
Guidance, Outlook, and Risks
The filing incorporates "Forward Looking Statements" from the attached press release by reference. No specific financial guidance or quantitative outlook is provided in the text of the Form 6-K itself. The filing notes that the press release is incorporated into the company's Registration Statements on Form S-8 and Form F-3.
Investor Verification Checklist
- Verify the full text of the press release (Exhibit 99.1) for specific clinical data and patient outcomes.
- Review the "Forward Looking Statements" section within the press release for associated risks and assumptions.
- Confirm the status of the ApoGraft technology pipeline and regulatory next steps.
- Check subsequent filings for any financial impact or funding requirements related to this trial.